Golimumab for severe asthma

Expert Opinion on Investigational Drugs

Volumn 18, Issue 9, 2009, Pages 1421-1423

  Antoniu, Sabina A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Asthma; Efficacy; Golimumab; Safety; TNF

Indexed keywords

CORTICOSTEROID; FLUTICASONE; GOLIMUMAB; PLACEBO;

ADD ON THERAPY; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INFECTION; MAJOR CLINICAL STUDY; NOTE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 68849088268     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903136716     Document Type: Note

References (6)

1. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006;354(7):697-708
2. Silvestri M, Bontempelli M, Giacomelli M, et al. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic inflammation? Clin Exp Allergy 2006;36(11):1373-81
3. Hutchison S, Choo-Kang BS, Bundick RV, et al. Tumour necrosis factor-alpha blockade suppresses murine allergic airways inflammation. Clin Exp Immunol 2008;151(1):114-22
4. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60(12):1012-8
5. Antoniu SA. Challenges in targeting TNFalpha in asthma and COPD. Curr Opin Investig Drugs 2009;10(5):404-6
6. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179(7):549-58